Key facts
as of Sep 2026- PrognomIQ’s last known valuation is $315.6M (Feb 2022).
- It has raised $171.8M across 3 recorded rounds; the latest was Early Stage VC ($11.9M) in Jan 2026.
- Notable investors include Emerson Collective, Wing Venture Capital, Catalio Capital Management, T. Rowe Price Group, Fidelity — 12 tracked in total.
- 1 institutional filer reports fund marks on PrognomIQ across 5 filings.
- PrognomIQ has filed 2 Form Ds with the SEC since 2024, most recently Aug 2025 ($10.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for PrognomIQ
Recorded secondary trades
No secondary trades in PrognomIQ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 5 fair-value marks on PrognomIQ between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
3 roundsAbout PrognomIQ
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2020
- Employees
- 49
- Website
- prognomiq.com/
- Ownership
- Privately Held (backing)